Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication
Viruses · 2023
DOI: 10.3390/v15020452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Shogo Nakajima und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agency for Medical Research and Development (AMED), Japan Society for the Promotion of Science KAKENHI, JST MIRAI program.
Abstract (Originalsprache)
Echinocandin antifungal drugs, including micafungin, anidulafungin, and caspofungin, have been recently reported to exhibit antiviral effects against various viruses such as flavivirus, alphavirus, and coronavirus. In this study, we focused on micafungin and its derivatives and analyzed their antiviral activities against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The micafungin derivatives Mi-2 and Mi-5 showed higher antiviral activity than micafungin, with 50% maximal inhibitory concentration (IC50) of 5.25 and 6.51 µM, respectively (3.8 to 4.7-fold stronger than micafungin) and 50% cytotoxic concentration (CC50) of >64 µM in VeroE6/TMPRSS2 cells. This high anti-SARS-CoV-2 activity was also conserved in human lung epithelial cell-derived Calu-3 cells. Micafungin, Mi-2, and Mi-5 were suggested to inhibit the intracellular virus replication process; additionally, these compounds were active against SARS-CoV-2 variants, including Delta (AY.122, hCoV-19/Japan/TY11-927/2021), Omicron (BA.1.18, hCoV-19/Japan/TY38-873/2021), a variant resistant to remdesivir (R10/E796G C799F), and a variant resistant to casirivimab/imdevimab antibody cocktail (E406W); thus, our results provide basic evidence for the potential use of micafungin derivatives for developing antiviral agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
- Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
- Choju Medical Institute, Fukushimura Hospital, 19-14 Yamanaka, Noyoricho, Toyohashi-shi 441-8124, Japan.
- Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan.
- Insect-Virus Interactions Unit, Department of Virology, Institut Pasteur, 75015 Paris, France.
- Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo 060-8638, Japan.
ORCID-Profile: Daisuke Akazawa, Takasuke Fukuhara
Förderung
- Agency for Medical Research and Development (AMED)
- Japan Society for the Promotion of Science KAKENHI
- JST MIRAI program
- Takeda Science Foundation
Zitieren
APA
Nakajima, S., Ohashi, H., Akazawa, D., Torii, S., Suzuki, R., Fukuhara, T., & Watashi, K. (2023). Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication. Viruses. https://doi.org/10.3390/v15020452
Vancouver
Nakajima S, Ohashi H, Akazawa D, Torii S, Suzuki R, Fukuhara T, et al. Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication. Viruses. 2023. doi:10.3390/v15020452
BibTeX
@article{Nakajima2023,
author = {Nakajima, Shogo and Ohashi, Hirofumi and Akazawa, Daisuke and Torii, Shiho and Suzuki, Rigel and Fukuhara, Takasuke and Watashi, Koichi},
title = {Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020452}
}
EUVIMED